Title:Low-dose Aspirin may Prevent Preeclampsia by Inhibiting the Expression
of ATF2
Volume: 23
Issue: 5
Author(s): Sha Xiao, Lu Guo, Ming Zhang, Rong Hu and Rong Liu*
Affiliation:
- Department of Obstetrics and Gynecology, Tianjin First Center Hospital, Tianjin 300192, China
Keywords:
Congenital adrenal hyperplasia, 11-beta hydroxylase deficiency, 11-deoxycortysol, CYP11B1 gene, mineralocorticoid pressure levels, ATF2.
Abstract:
Aims: To explore the ATF2 expression of preeclampsia patients and investigate
whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia
patients.
Background: Preeclampsia is a severe pregnancy-related hypertension disorder and refers to hypertension.
Objective: This study was designed to explore the activating transcription factor 2 (ATF2) expression
of preeclampsia patients and investigate whether the level of ATF2 expression impacted the
low-dose aspirin treatment of preeclampsia patients.
Methods: Firstly, we collected the plasma of normal and preeclampsia pregnancies and quantified
the expressions of ATF2 by ELISA. Then we quantified the expression of the three downstream
target genes of ATF2 (IL-8, IL-6 and MMP-2). Finally, we collected and quantified the interventional
and observational group plasma. All data were compared by t-test (p<0.05).
Results: ATF2 and its target genes (IL-6, IL-8 and MMP-2) were upregulated in preeclampsia
patients. In addition, ATF2 and its target genes were downregulated in the interventional group
(LDA-treated group).
Conclusion: Our results indicated that LDA could inhibit ATF2 expression in preeclampsia. It
suggests that ATF2 may be a potential target of LDA in the prevention of preeclampsia.
